DFS70

Product Information

Antinuclear antibodies (ANA) are helpful laboratory markers to support the diagnosis of ANA- associated rheumatic diseases (AARD) such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS), mixed connective tissue disease (MCTD), and systemic sclerosis (Ssc). The ANA presence has also been detected at lower frequency in patients with cancer and diverse inflammatory conditions.

Anti Dense Fine Speckled 70 (DFS70) antibodies have been identified to be associated with specific ANA pattern characterized by irregularly distributed, fine granular fluorescence of the nuclei in the interphase and of the metaphase chromatin. Unlike other ANA, anti-DFS70 antibodies are not prevalent in AARD, anti-DFS70 antibodies have been detected at elevated frequency in apparently healthy individuals and various inflammatory conditions such as dermatitis, psoriasis, interstitial cystitis, ocular diseases, chronic fatigue syndrome, asthma, or prostate cancer.

The current knowledge, provided by diverse clinical studies, shows that higher titres of anti-DFS70 antibodies (without being accompanied by other antibodies) are useful to aid in the exclusion of ANA associated rheumatic diseases.

DFS70, also known as lens epithelium growth- derived factor (LEGDF) or transcription co-activator p75, is a 62 kDa protein. DFS70 comprises a N-terminal PWWP domain and C-terminal integrase binding domain. This protein is involved in the upregulation of some stress protective and inflammatory genes.

AROTEC DFS70 is recombinantly expressed as a full-length protein in insect cells. This protein is soluble and it is fused to a hexahistidine tag.

Clinical Indications

Asthma | Atopic dermatitis | Negative predictive marker for SARD

Certificate of Analysis

Please log in to view certificates of analysis for this item

MSDS

References

1. Bossuyt, X. (2024). DFS70 Autoantibodies:  Clinical Utility in Antinuclear Antibody Testing. Clinical Chemistry, 70(2), 374–381.
2. Carbone, T., Pafundi, V., Tramontano, G., Gilio, M., Padula, M. C., Padula, A. A., & D’Angelo, S. (2019). Prevalence and serological profile of anti-DFS70 positive subjects from a routine ANA cohort. Scientific Reports, 9(1). https://doi.org/10.1038/s41598-019-38686-5
3. Carter, J. B., Carter, S., Saschenbrecker, S., & Goeckeritz, B. E. (2018). Recognition and Relevance of Anti-DFS70 Autoantibodies in Routine Antinuclear Autoantibodies Testing at a Community Hospital. Frontiers in Medicine, 5(88).
4. Chan, E. K. L., Damoiseaux, J., Carballo, O. G., Conrad, K., de Melo Cruvinel, W., Francescantonio, P. L. C., Fritzler, M. J., Garcia-De La Torre, I., Herold, M., Mimori, T., Satoh, M., von Mühlen, C. A., & Andrade, L. E. C. (2015). Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) 2014-2015. Frontiers in Immunology, 6(JUL). https://doi.org/10.3389/fimmu.2015.00412
5. Lux, V., Brouns, T., Čermáková, K., Srb, P., Fábry, M., Mádlíková, M., Hořejší, M., Kukačka, Z., Novák, P., Kugler, M., Brynda, J., DeRijck, J., Christ, F., Debyser, Z., & Veverka, V. (2020). Molecular Mechanism of LEDGF/p75 Dimerization. Structure, 28(12), 1288-1299.e7. https://doi.org/10.1016/j.str.2020.08.012
6. Mahler, M., Andrade, L. E., Casiano, C. A., Malyavantham, K., & Friztler, M. J. (2019). Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness. Expert Review of Clinical Immunology.
7. Mahler, M., Parker, T., Peebles, C. L., Andrade, L. E., Swart, A., Carbone, Y., Ferguson, D. J., Villalta, D., Bizzaro, N., Hanly, J. G., & Fritzler, M. J. (2012). Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. Journal of Rheumatology, 39(11), 2104–2110. https://doi.org/10.3899/jrheum.120598
8. Ochs, R. L., Mahler, M., Basu, A., Rios-Colon, L., Sanchez, T. W., Andrade, L. E., Fritzler, M. J., & Casiano, C. A. (2016). The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin Exp Med, 16, 273–293.
9. Ortiz-Hernandez, G. L., Sanchez-Hernandez, E. S., & Casiano, C. A. (2020). Twenty years of research on DFS70/LEGDF autoantibody-autoantigen system: many lessons learned but still many questions. Autoimmunity Highlights, 11(3). https://doi.org/10.1186/s!3317-020-0126-4
10. Wang, H., Farnung, L., Dienemann, C., & Cramer, P. (2020). Structure of H3K36-methylated nucleosome–PWWP complex reveals multivalent cross-gyre binding. Nature Structural and Molecular Biology, 27(1), 8–13. https://doi.org/10.1038/s41594-019-0345-4